|
Liver carcinoma
|
1.000 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
HPO |
|
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Expression of c-met was determined by Northern-blot hybridization of a specific probe (human met proto-oncogene) in 18 tumoral and nontumoral liver samples obtained in 18 cirrhotic patients with hepatocellular carcinoma submitted to surgical treatment.
|
8276372 |
1994 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tissue localization studies of HGF and its receptor c-met protein support the existence of both autocrine and paracrine mechanisms of action of HGF in HCC vs only a paracrine mechanism in normal liver.
|
9010472 |
1997 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
|
9096589 |
1997 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
UNIPROT |
Our results indicate that mutations of the tyrosine kinase domain of the MET gene may be involved in the acceleration of the carcinogenesis in childhood HCC.
|
9927037 |
1999 |
|
Liver carcinoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that mutations of the tyrosine kinase domain of the MET gene may be involved in the acceleration of the carcinogenesis in childhood HCC.
|
9927037 |
1999 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Transfection of various c-met-CAT promoter constructs into the mouse hepatocellular carcinoma cell line Hepa 1-6 in combination with electrophoretic mobility shift assays (EMSA) identified the responsive element as an activated protein-1 (AP-1) binding site (TGAGTCA) within the c-met core promoter region at position -158 to -152.
|
10713700 |
2000 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.
|
10925356 |
2000 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice.
|
11381087 |
2001 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the ability of a retroviral amphotropic envelope displaying single-chain variable-fragment (scFv) directed against the c-Met receptor, to target the entry of recombinant retroviruses to human hepatocarcinoma cells.
|
14605670 |
2003 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Amphotropic retroviruses with modified envelope displaying single-chain antibody fragment (scFv) directed against the c-Met receptor were recently generated and found to efficiently and selectively deliver genes into hepatocarcinoma cells.
|
16082194 |
2005 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
|
16331686 |
2006 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
LHGDN |
Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype.
|
16710476 |
2006 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Prostaglandin E2 receptor EP1 transactivates EGFR/MET receptor tyrosine kinases and enhances invasiveness in human hepatocellular carcinoma cells.
|
16331686 |
2006 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
RGD |
Specificity for the binding of the molecularly targeted anti-c-MET contrast agent was determined using rat hepatoma (H4-II-E-C3) cell cultures and immunofluorescence microscopic imaging of the targeting agents within neoplastic liver tissue 1 to 2 hours following intravenous administration of SPIO-anti-c-MET and MRI investigation.
|
17311762 |
2007 |
|
Liver carcinoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Inactivation of MET transgenes led to regression of hepatocellular carcinomas despite the persistence of activated beta-catenin.
|
17785413 |
2007 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.
|
17992475 |
2008 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
LHGDN |
Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
|
19065669 |
2009 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
These encode genes, such as EGFR and MET, previously associated with HCC and others, such as UBE2H, that are potential new targets for treating this neoplasm.
|
19234449 |
2009 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated by P-gp in MDR-positive human hepatocellular carcinoma cell line.
|
19447220 |
2009 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
However, in our recently published studies, we have documented that AAV3 vectors transduce human liver cancer - hepatoblastoma (HB) and hepatocellular carcinoma (HCC) - cell lines extremely efficiently because AAV3 utilizes human hepatocyte growth factor receptor as a cellular co-receptor for binding and entry in these cells.
|
21445055 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Tissue samples were obtained from tumor (TU), adjacent non-tumor (AN) and distant normal (DN) liver in Tet-operator regulated (TRE) human c-MET transgenic mice (n = 21) as well as from a Chinese cohort of 272 HBV- and 9 HCV-associated HCC patients.
|
21949730 |
2011 |
|
Liver carcinoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Identification of a malignant stemlike subtype of HCC may offer patients with a dismal prognosis a potential targeted therapy using c-MET and Wnt pathway inhibitors.
|
21737452 |
2011 |